An Expert Approach to Cardio-Renal Protection in CKD: Part Two
Published: 07 May 2024
-
Views:
3899
-
Likes:
7
-
Views:
3899
-
Likes:
7
-
Up Next
-
1m 46sPart 3 | Session 3 Do we start an SGLT2 inhibitor or RAASI therapy first?
-
1m 21sPart 3 | Session 4 Is one ACE inhibitor better than an other for patients with CKD?
-
1m 23sPart 3 | Session 5 Are SGLT2 inhibitors suitable for patients with high cardiovasular risk?
-
3m 11sPart 3 | Session 6 Key Summary
-
19m 38sPart 1 Review of Recommendations Navdeep Tangri, James Burton, David Wheeler
-
14m 54sPart 2 | Session 1 Applying KDIGO Guidelines to a Patient Case James Burton, Navdeep Tangri, David Wheeler
-
8m 27sPart 2 | Session 2 KDIGO Guidelines and Individualising Care James Burton, Navdeep Tangri, David Wheeler
-
52sPart 3 | Session 1 Do you continue SGLT2 inhibitors in patients on dialysis? James Burton
Overview
Chaired by Prof James Burton (University of Leicester, UK), this roundtable features expert insight from a world-renowned faculty, Prof David Wheeler (University College London, UK) and Dr Navdeep Tangri (University of Manitoba, CA).
Dr Tangri begins by providing an overview of the recent KDIGO guideline updates. Following this, the panel recap on the patient case that was presented in part one of this programme. The faculty discuss why the guidelines were updated and how the updates may impact the management strategy of the patient. They continue to provide practical advice for initiating cardiorenal protection therapy in non-diabetic CKD patients.
Note, the live version of this session was CME accredited; this on-demand version is not.
Key Learning Objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
Target Audience
- Cardiologists
- Nephrologists
- Heart Failure Specialists
- Primary Care Physicians
More from this programme
Part 1
Review of Recommendations
1 session | |
Review of Recommendations | Watch now |
Part 2
Panel Discussion
Part 3
Audience Q&A / Key Summary
Faculty Biographies
![James Burton](https://assets.radcliffecardiology.com/s3fs-public/author/2022-11/Screenshot%202022-11-15%20120029.png?VersionId=lyLygep2hgx9PUHo73fp6LTpVDftep8u)
James Burton
Professor of Renal Medicine
Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.
In addition Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.
He is the current Chair of the UK Kidney Association Clinical…
Comments